![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Despite the lack of long-term survival data, the impressive results obtained with fludarabine- and rituximab-based therapies have altered the philosophy of the management of patients with chronic lymphocytic leukaemia (CLL). Therapy with chemoimmunotherapy appears to give higher responses with more patients achieving complete remission and some molecular remission. This may potentially translate into improved disease-free survival, and potentially a ‘cure’. Treatment options for patients who develop resistance to fludarabine continue to be limited. This review summarises current chemo-, immuno-, and chemoimmunotherapeutic regimens that are being currently evaluated in patients with CLL.